ISRCTN11052603 https://doi.org/10.1186/ISRCTN11052603

Phase I trial: MM-120-101

Submission date 14/05/2024	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 21/05/2024	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 29/06/2026	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr David Gregory

Contact details
11 Tiger Court, Kings Drive Prescot
Liverpool
United Kingdom
L34 1BH
+44 (0)151 4824700
davidgregory@macplc.com

Type(s)
Scientific

Contact name
None Jo Brady

Contact details
Senior Consultant
DLRC Regulatory Consultancy
Suite 201, The Nexus Building, Broadway
Letchworth Garden City
United Kingdom
Herts SG6 3TA

+44 01462 372472
Jo.Brady@dlrcgroup.com

Additional identifiers

Integrated Research Application System (IRAS)
1007602

Study information

Scientific Title
Phase I trial: MM-120-101

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 18/09/2023, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, East Cardiff, CF11 9AB, United Kingdom; 02922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0112

Primary study design
Other

Study design
Phase 1 study in 30 healthy volunteers

Study type(s)
Other, Safety

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
19/12/2023

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
0

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
13/10/2023

Date of final enrolment
04/12/2023

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MAC Clinical Research Liverpool
11 Tiger Court
King's Business Park
Liverpool
England
L34 1BH

Study participating centre
MAC Clinical Research Manchester
Citylabs 1.0
Nelson St
Manchester
England
M13 9NQ

Sponsor information

Organisation
Mind Medicine Inc

Funder(s)

Funder type
Research organisation

Funder Name
Mind Medicine Inc

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available